Further, the activated mTOR pathway which results in phosphorylated 4EBP1 and S6K leads to higher levels of CyclinD1 [36,37,38], while the inhibition of PI3K/AKT/mTOR/S6K leads to decreased CyclinD1 expression in cancer cells [38,39]. The gene discussed is MTOR; the disease is cancer.